UnitedHealth Is Dirt Cheap -- Yet The Comeback Won't Be Quick

UnitedHealth is deeply undervalued, trading at low P/E and P/FCF multiples despite long-term growth potential and a wide economic moat. Short-term challenges persist: earnings are down, CEO resigned, DoJ investigation ongoing, and higher medical costs are pressuring margins. Management and analysts remain optimistic about a return to double-digit growth, but a quick recovery is unlikely; patience is required.